Compare Bath & Body Works Inc (BBWI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Sanofi SA — how do they compare? Bath & Body Works Inc trades at $19 (market cap $3.81B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 27.4× Bath & Body Works Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BBWI | SNY | |
|---|---|---|
Market Cap | $3.81B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $52.34 |
52-Week Low | $14.85 | $41.33 |
Enterprise Value | $7.70B | $124.19B |
Dividend Yield | 4.24% | 5.55% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
